Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175639 | 1.00 | BRAF (0.41) | BRAFPPME1EGFRERBB2HSP90AA1 | |
| SCHEMBL4175645 | 1.00 | BRAF (0.41) | BRAFPPME1EGFRERBB2HSP90AA1 | |
| SCHEMBL4172187 | 0.88 | PKM (0.44) | BRAFPPME1EGFRERBB2PKM | |
| SCHEMBL4172185 | 0.88 | PKM (0.44) | BRAFPPME1EGFRERBB2PKM | |
| SCHEMBL4172179 | 0.88 | PKM (0.44) | BRAFPPME1EGFRERBB2PKM | |
| SCHEMBL4182683 | 0.85 | EGFR (0.36) | EGFRERBB2PKMKMT2APOLB | |
| SCHEMBL4182685 | 0.85 | EGFR (0.36) | EGFRERBB2PKMKMT2APOLB | |
| SCHEMBL4182678 | 0.85 | EGFR (0.36) | EGFRERBB2PKMKMT2APOLB | |
| SCHEMBL4191715 | 0.85 | BRAF (0.45) | BRAFPPME1EGFRHSP90AA1PKM | |
| SCHEMBL4191711 | 0.85 | BRAF (0.45) | BRAFPPME1EGFRHSP90AA1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | claimed |
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | BRAF 372/4885PPME1 2181/4885EGFR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.